Insulin-like growth factor-i deficiency in children with growth hormone insensitivity: Current and future treatment options

BioDrugs

Volumn 23, Issue 3, 2009, Pages 155-163

  Kemp, Stephen F ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; JANUS KINASE; MECASERMIN RINFABATE; NEUTRALIZING ANTIBODY; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN; STAT PROTEIN;

CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENZYME ACTIVATION; FACIAL NERVE PARALYSIS; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE INSENSITIVITY; GROWTH HORMONE RELEASE; GROWTH RATE; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; HYPOGLYCEMIA; IDIOPATHIC DISEASE; INJECTION SITE PAIN; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; INTRACRANIAL HYPERTENSION; KIDNEY HYPERTROPHY; LARON SYNDROME; LIPOHYPERTROPHY; LIVER; LONG TERM CARE; MIDDLE EAR EFFUSION; MONOTHERAPY; NONHUMAN; PAPILLEDEMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SEIZURE; SHORT STATURE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPLENOMEGALY; TONSIL DISEASE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

CHILD; CLINICAL TRIALS AS TOPIC; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LARON SYNDROME; RECOMBINANT PROTEINS;

EID: 68649125888     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/00063030-200923030-00002     Document Type: Review

References (57)

1. Parks JS, Nielson PV, Sexton LA, et al. An effect of gene dosage on production of human chorionic somatomammotropin. J Clin Endocrinol Metab 1985; 50 (5): 994-7
2. Chen EY, Liao YC, Smith DH, et al. The human growth hormone locus: nucleotide sequence, biology and evolution. Genomics 1989; 4: 479-97
3. Cooke NE, Ray J, Watson MA, et al. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. J Clin Invest 1988 Jul; 82 (1): 270-5
4. Rosenfeld RG. The IGF system: new developments relevant to pediatric practice. Endocr Dev 2005; 9: 1-10
5. Rinderknecht E, Humbel RE. Primary structure of human insulin-like growth factor II. FEBS Lett 1978; 89: 283-6
6. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76
7. Nilsson O, Marino R, DeLuca F, et al. Endocrine regulation of the growth plate. Horm Res 2005; 64: 157-65
8. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140-4
9. Jorgensen JOL, Blum WF, Moller N, et al. Short-term changes in insulin-like growth factors (IGF's) and IGF-binding protein-3 after different modes of intravenous growth hormone (GH) exposure to GH-deficient patients. J Clin Endocrinol Metab 1991; 72: 582-7
10. Sjogren K, Liu J-L, Blad K, et al. Liver-derived insulin-like growth factor-I (IGF-I) is the principle source of IGF-I in blood but is not required for postnatal growth in mice. Proc Natl Acad Sci U S A 1999; 96: 7088-92
11. Yakar S, Rosen CJ, Beamer WG, et al. Circulation levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002; 110: 771-81
12. Binoux M. IGF-binding protein-3 and acid-labile subunit: What is the pecking order? Eur J Endocrinol 1997; 137: 605-9
13. Ooi GT, Cohen FJ, Tseng L-H, etal. Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulinlike growth factor-binding protein complex and ALS promoter activity in rat liver. Mol Endocrinol 1997; 11: 997-1007
14. Rosenfeld RG, Belgorosky A, Camacho-Hubner C, et al. Defects in growth hormone receptor signalling. Trends Endocrinol Metab 2007; 18: 134-41
15. Fuh G, Cunningham BC, Fukunaga R, et al. Rational design of potent antagonists to the human growth hormone receptor. Science 1992; 256: 1677-80
16. Waters MJ, Hoang HN, Fairlie DP, et al. New insights into growth hormone action. J Mol Endocrinol 2006; 36: 1-7
17. Yi W, Kim SO, Jiang J, et al. Growth hormone receptor cytoplasmic domain differentially promotes tyrosine phosphorylation of signal transducers and activators of transcription 5b and 3 by activated JAK2 kinase. Mol Endocrinol 1996; 10: 1425-43
18. Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulatessulfate incorporationby cartilagein vitro.JLab Clin Med 1957; 49: 825-36
19. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1995; 47: 1-114
20. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentrations of growth hormone: a new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-5
21. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to pituitary GH receptor deficiency. Endocr Rev 1994; 15: 369-90
22. Laron Z, Lillos P, Linger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68: 768-70
23. Rosenbloom AL. IGF-I treatment of growth hormone insensitivity. In: Rosenfeld RG, Roberts CT, editors. IGF in health and disease. Totowa (NJ): Humana Press, 2000: 739-70
24. Savage MO, Burren CP, Blair JC, et al. Growth hormone insensitivity: pathophysiology, diagnosis, clinical variation and future perspective. Horm Res 2001; 55 Suppl. 2: 32-5
25. Johnson LB. The broad spectrum of inherited growth hormone insensitivity syndrome. Trends Endocrinol Metab 1998; 9: 228-32
26. Kofoed EM, Hwa V, Little B, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003; 349 (12): 1110-2
27. Woods KA, Camacho-Hubner C, Savage MO, et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulinlike growth factor I gene. N Engl J Med 1996; 335: 1363-7
28. Domene H, Bengolea SV, Martinez AS, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350: 570-7
29. Savage MO, Camacho-Hubner C, David A, et al. Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy? Eur J Endo-crinol 2007; 157 Suppl. 1: S33-7
30. Collett-Solberg PF, Misra M. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93: 10-8
31. Guevara-Aguirre J, Vasconez O, Martinez V, et al. A randomized double-blind, placebo controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-8
32. Savage MO, Camacho-Hubner C, Dunger D. Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res 2004; 14: 301-8
33. Rosenfeld RG. IGF-I therapy in growth disorders. Eur J Endocrinol 2007; 157 Suppl. 1: S57-60
34. Laron Z, Anin S, Klipper-Auerbach Y, et al. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-61
35. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulinlike growth factor-I in 22 children: comparison of two dosage levels and to GH-treated Gh deficiency. J Clin Endocrinol Metab 1997; 82 (2): 629-33
36. Ranke MB, Savage MO, Chatelain PG, et al. Treatment of growth hormone insensitivity syndrome with insulin-like growth factor: I. Long-term results of the European Multicentre study. Horm Res 1999; 51: 128-34
37. Backeljauw PF, Underwood LE, Group TGC. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001; 86: 1504-10
38. Backeljauw PF, Chernausek SD. Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans. Horm Res 2006 Mar 2; 65 Suppl. 1: 21-7
39. Azcona C, Preece MA, Rose SJ, et al. Growth response to rhIGF-I 80 ug/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of phenotype. Clin Endocrinol 1999; 51: 787-92
40. Ranke MB, Wollman HA, Savage MO. Experience with insulin-like growth factor I(IGF)-I treatmentofgrowth hormone insensitivity syndrome (GHIS). J Pediatr Endocrinol Metab 1999; 12: 259-66
41. Chernausek SD, Backeljauw PF, Frane J, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-10
42. Camacho-Hubner C, Underwood LE, Yordam N, et al. Once daily rhIGF-1/rhIGFBP-3 treatment improves growth in children with severe primary IGF-I deficiency: results of a multicenter clinical trial [abstract]. 88th Annual Meeting, The Endocrine Society; 2006 Jun 24-28; Boston (MA)
43. Camacho-Hubner C, Rose SJ, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006; 91 (4): 1246-53
44. Camacho-Hubner C, Woods KA, Miraki-Moud F, et al. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGFsystem of a patient with a partial IGF-gene deletion. J Clin Endocrinol Metab 1999; 84: 1611-6
45. Woods KA, Camacho-Hubner C, Bergman RN, et al. Effects of insulinlike growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000; 85: 1407-11
46. Attie KM, Carlsson LM, Chen Rundle A, et al. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatrics 1995; 127: 244-50
47. Goddard AD, Covello R, Luoh S-M, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. N Engl J Med 1995; 333: 1093-8
48. Blethen S, Hertz J, Kuntze J, et al. The Increlex Growth Forum Database Registry: a Web-based patient registry for monitoring long-term safety and efficacy of Increlex treatment [abstract no. P1-466]. 89th Annual Meeting; The Endocrine Society; 2007 June 2-5; Toronto (ON)
49. Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I in the treatment of idiopathic short stature? Lancet 2006 Aug; 368 (9535): 612-6
50. Rosenbloom AL. The role of recombinant insulin-like growth factor I in the treatment of the short child. Curr Opin Pediatr 2007; 19 (4): 458-64
51. Rosenbloom AL. Insulin-like growth factor-I (rhIGF-I) therapy of short stature. J Pediatr Endocrinol Metab 2008; 21 (4): 301-15
52. Reidl S, Frisch H. Effects of growth hormone (GH) and insulin-like growth factor-I therapy in patients with gene defects in the GH axis. J Pediatr Endocrinol Metab 2006; 19: 229-36
53. Grahnen A, Kastrup K, Heinrich U, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr 1993; 82 Suppl. 391: 9-13
54. Ranke MB. Treatment of growth hormone insensitivity syndrome (GHIS) with insulin-like growth factor (IGF-I). Baillieres Clin Endocrinol Metab 1996; 10: 401-10
55. Clemmons DR, Moses AC, Sommer A, et al. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 2005; 15 (4): 165-74
56. Quattrin T, Thrailkill KM, Baker L, et al. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM: effects on glycemic control, IGF-I levels, and safety profile. Diabetes Care 1997; 20 (3): 374-80
57. Camacho-Hubner C, Storr HL, Miraki-Moud F, et al. Pharmacokinetic studies of rhIGF-I/rhIGFBP-3 complex administered to patients with growth hormone insensitivity syndrome (GHIS) [abstract]. 85th Annual Meeting, the Endocrine Society; 2003 Jun 19-22; Philadelphia (PA)